Haze in Singapore: Evidence-Based Guidance for GPs on COPD and Asthma

Purpose

Consolidated guidance for general practitioners counselling patients during haze episodes in Singapore (PM2.5-predominant particulate exposure from regional biomass burning), covering general population advice, COPD exacerbation management, and asthma management.

1. General Population Advice

Monitor air quality and calibrate activity. Advise patients to check PSI/PM2.5 readings (e.g., NEA MyENV app) before outdoor activity and to reduce or reschedule outdoor exertion as readings rise, since exercise increases minute ventilation and total inhaled pollutant dose. Progressively curtail outdoor activity duration and intensity at higher PSI/AQI levels (Carlsten et al., European Respiratory Journal, 2020; Rajagopalan et al., Circulation, 2020).

Vulnerable groups requiring targeted counselling:

• Asthma/COPD: avoid unnecessary outdoor activity, especially vigorous exercise, on hazy days; continue/optimise maintenance inhaled corticosteroid therapy (Guarnieri and Balmes, Lancet, 2014).
• Cardiovascular disease, diabetes, obesity, age over 65: higher mortality risk with PM2.5 exposure; prioritise personal protective measures and risk-factor optimisation (Rajagopalan et al., Circulation, 2020).
• Pregnant women and children: more conservative activity limits; N95 masks can be safely worn by children aged 7 and above (cloth masks unreliable); balance indoor-sheltering advice against maintaining prenatal visits, using recirculated vehicle air if travel is necessary (Crocker and Cogen, Pediatric Pulmonology, 2026; Wardle et al., Journal of Exposure Science and Environmental Epidemiology, 2026).

Indoor air quality measures. Close windows/doors during haze, use air-conditioning in recirculation mode in vehicles, and use a portable HEPA air cleaner or a MERV 7–13 HVAC filter where available, particularly in the room where a vulnerable patient sleeps.

Face masks. Properly fitted N95/N99 respirators meaningfully reduce PM2.5 inhalation and are recommended for outdoor use during high-PSI episodes, especially for susceptible individuals; surgical masks offer limited benefit and cloth masks are not reliable.

Other counselling points: avoid cooking with solid fuels and ensure good ventilation when cooking; avoid concurrent exposures such as secondhand smoke; seek prompt medical attention for worsening respiratory or cardiac symptoms during haze.

Note: this general guidance is extrapolated largely from particulate matter/wildfire-smoke literature rather than Singapore-specific haze trials, though the underlying pollutant (PM2.5) and physiologic risks are the same.

2. COPD: Haze-Related Exacerbation Management

Acute exacerbation management is unchanged by the trigger being haze versus another cause:

• Short-acting beta-agonists (SABA), with or without short-acting anticholinergics, first-line for moderate/severe exacerbations.
• Systemic corticosteroids for up to 5 days in moderate/severe exacerbations.
• Antibiotics for 5 days only if purulent sputum, prior lung infection history, or features suggesting bacterial superinfection. Haze exposure alone does not mandate antibiotics.
• Oxygen/ventilatory support: controlled oxygen for hypoxaemia; high-flow nasal therapy or non-invasive ventilation for impending respiratory failure.
• Hospitalisation triggers: worsening hypoxaemia, altered mental status, haemodynamic instability, or failure of outpatient therapy.
• Exclude mimics: pneumonia, pulmonary embolism, acute heart failure, pneumothorax.

(Pocket Guide to COPD Diagnosis, Management, and Prevention, 2026 Report)

Haze-specific prevention and counselling:

• Pre-emptive increase in reliever/controller inhaler use before anticipated high pollution exposure is biologically plausible but not established as clinically beneficial in trials (see evidence summary below).
• Daily air quality monitoring with curtailment of outdoor activity when particulate levels rise.
• Indoor air filtration is a particularly actionable, better-supported measure for COPD patients.
• Properly fitted respirator masks can reduce exposure but have limited evidence for improving hard clinical outcomes, and may cause discomfort or false reassurance.
• Avoid unproven alert-based avoidance systems without individualisation. One study found telephone/alert-based systems associated with increased hospital attendance rather than reduced risk (Cochrane review, Janjua et al., 2021).

Post-exacerbation follow-up: recovery can take 4–6 weeks; optimise maintenance long-acting bronchodilator therapy promptly, adding ICS to dual bronchodilator therapy at discharge if ≥1 moderate/severe exacerbation occurred with elevated blood eosinophils. Long-term air pollution exposure is independently associated with increased exacerbation risk, so haze mitigation should be part of the overall exacerbation-prevention plan.

Evidence on pre-emptive dose escalation in COPD: Short-term pollutant exposure is a genuine, dose-related, non-infectious exacerbation trigger. A CanCOLD cohort case-crossover study found increased NO2 associated with exacerbations at lag-3 in warm season (OR 1.14, 95% CI 1.01–1.29 per IQR) and increased PM associated with exacerbations at lag-1 in cool season (OR 1.11, 95% CI 1.03–1.20 per IQR) (Ross et al., Thorax, 2023). A Korean time-stratified case-crossover study found pollutant-mixture effects on exacerbation risk peaking at lag 0 in spring (OR 1.19, 95% CI 1.04–1.34) and persisting through winter (OR 1.20–1.28), strongest in men, adults 65 and older, current smokers, and BMI ≥25 (Kim et al., Ecotoxicology and Environmental Safety, 2026). Despite this causal link, the Cochrane review specifically addressing pre-emptive pharmacological strategies found no trial evidence that proactively increasing inhaler doses before exposure reduces exacerbation risk. Existing data show only that patients reactively use more inhaler once air quality worsens, likely responding to symptoms already present (Janjua et al., Cochrane Database of Systematic Reviews, 2021). ICS efficacy in COPD is independently debated given relative corticosteroid resistance from oxidative stress and neutrophilic inflammation, further weakening the rationale for pollution-triggered dose escalation (Criner et al., Chest, 2015).

Practical takeaway for COPD: pre-emptive bronchodilator/ICS escalation may be discussed as a plausible, low-risk option for engaged patients, but should not be framed as evidence-based prevention. Prioritise indoor air filtration, reduced outdoor exertion during poor air quality, and ensuring maintenance therapy is already optimised.

3. Asthma: Haze-Related Management

Unlike COPD, asthma has an established evidence base for symptom-triggered ICS dose escalation, which is directly applicable to haze management, though it is not haze-specific trial evidence.

Action plans. The Global Initiative for Asthma (GINA) recommends at least doubling (in some protocols increasing to a high dose) ICS-containing maintenance therapy when symptoms worsen, reliever use increases, or peak expiratory flow falls more than 20% for over two days. This patient-initiated, action-plan-based approach is standard practice, validated by a Cochrane review of increased versus stable ICS doses for exacerbations (though a major pragmatic NIHR-funded trial addressing effectiveness/safety was excluded from that meta-analysis for design reasons, leaving some uncertainty about the magnitude of benefit even outside the pollution context).

Haze as a legitimate trigger. Short-term exposure to PM2.5, PM10, and NO2 probably increases asthma-related hospital admissions and emergency visits (moderate-certainty evidence, EAACI systematic review), supporting haze exposure as grounds to activate an existing written action plan rather than waiting passively for symptoms to worsen. An East London primary care cohort found NO2, PM10, and PM2.5 elevations associated with increased mild exacerbation risk, with the strongest signal in patients with recent blood eosinophilia. This raises an untested hypothesis that biomarker-directed ICS stepping could be relevant for eosinophilic phenotypes, though this strategy itself was not tested for reducing pollution-related risk.

Purely prophylactic (pre-symptom) escalation remains unproven. As with COPD, the Cochrane review on individual-level pollution-exposure interventions found increased inhaler use correlates with poorer air quality, but it remains unclear whether increasing use prophylactically, before symptoms develop, provides benefit beyond reactive use once symptoms are present.

Caveats. Maintenance ICS adherence ahead of haze season has stronger support than reactive dose-doubling specifically for haze. Patients with severe asthma may have persistent symptoms with pollutant exposure despite steroid treatment, and there is modest mechanistic evidence that air pollution, like cigarette smoke, may induce partial glucocorticoid resistance, potentially blunting the expected benefit of dose escalation.

Practical takeaway for asthma: ensure every patient has a written action plan with clear criteria (symptoms, reliever use, PEF decline >20% for ≥2 days) for stepping up ICS; reinforce that haze exposure, especially with exertion, is a legitimate trigger to activate the plan early; confirm maintenance therapy adherence before haze season; advise indoor avoidance/filtration on high-PSI days as a complementary, better-evidenced measure alongside, not instead of, action-plan-based ICS adjustment.

References

1. Personal Strategies to Minimise Effects of Air Pollution on Respiratory Health: Advice for Providers, Patients and the Public. The European Respiratory Journal. 2020. Carlsten C, Salvi S, Wong GWK, Chung KF.
2. Outdoor Air Pollution and Asthma. Lancet. 2014. Guarnieri M, Balmes JR.
3. Wildfire Smoke and Pediatric Lung Health: What the Clinician Needs to Know. Pediatric Pulmonology. 2026. Crocker ME, Cogen JD.
4. Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association. Circulation. 2020. Rajagopalan S, Brauer M, Bhatnagar A, et al.
5. Pocket Guide to COPD Diagnosis, Management, and Prevention: 2026 Report. Global Initiative for Chronic Obstructive Lung Disease. 2025.
6. Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions. Cochrane Database of Systematic Reviews. 2021. Janjua S, Powell P, Atkinson R, et al.
7. Short-Term Air Pollution Exposure and Exacerbation Events in Mild to Moderate COPD: A Case-Crossover Study Within the CanCOLD Cohort. Thorax. 2023. Ross BA, Doiron D, Benedetti A, et al.
8. Short-Term Exposure to Air Pollutant Mixtures and Seasonal Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Time-Stratified Case-Crossover Study. Ecotoxicology and Environmental Safety. 2026. Kim CH, Kang YH, Kim S, et al.
9. Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015. Criner GJ, Bourbeau J, Diekemper RL, et al.